Alikhani MS et al., 2026-10-23: PRISMA 2020 systematic review (1990 to April 2026) of antiviral photodynamic inactivation and therapy that deliberately separates ex vivo pathogen reduction from in vivo treatment , the distinction this claim turns on.
This systematic review synthesizes available data on photosensitizer-mediated antiviral effects, therapeutic applications, and limitations, explicitly distinguishing PDI (ex vivo/environmental inactivation) from PDT (in vivo treatment).
Abstract
Alikhani MS et al., 2026-10-23: PRISMA 2020 systematic review (1990 to April 2026) of antiviral photodynamic inactivation and therapy that deliberately separates ex vivo pathogen reduction from in vivo treatment , the distinction this claim turns on. Study type: systematic review (PubMed, Scopus, Web of Science, Embase), two independent reviewers. Excludes studies using UV without a photosensitiser and light-independent mechanisms. Countries: international (Iran-based author group). MB is one of the photosensitisers covered, not the only one. Competing interests: none declared. Bearing: supports that a large PDI literature exists, while its explicit 'translational boundaries' framing is a caution against reading ex vivo inactivation as clinical therapy. Published October 2026 , the most recent item in C3. Study type: review.
